Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging.
demyelination
diffusion microstructural modelling
multiple sclerosis
myelin water imaging
neurodegeneration
Journal
Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537
Informations de publication
Date de publication:
28 07 2021
28 07 2021
Historique:
received:
26
07
2020
revised:
29
12
2020
accepted:
03
01
2021
pubmed:
12
3
2021
medline:
25
9
2021
entrez:
11
3
2021
Statut:
ppublish
Résumé
Damage to the myelin sheath and the neuroaxonal unit is a cardinal feature of multiple sclerosis; however, a detailed characterization of the interaction between myelin and axon damage in vivo remains challenging. We applied myelin water and multi-shell diffusion imaging to quantify the relative damage to myelin and axons (i) among different lesion types; (ii) in normal-appearing tissue; and (iii) across multiple sclerosis clinical subtypes and healthy controls. We also assessed the relation of focal myelin/axon damage with disability and serum neurofilament light chain as a global biological measure of neuroaxonal damage. Ninety-one multiple sclerosis patients (62 relapsing-remitting, 29 progressive) and 72 healthy controls were enrolled in the study. Differences in myelin water fraction and neurite density index were substantial when lesions were compared to healthy control subjects and normal-appearing multiple sclerosis tissue: both white matter and cortical lesions exhibited a decreased myelin water fraction and neurite density index compared with healthy (P < 0.0001) and peri-plaque white matter (P < 0.0001). Periventricular lesions showed decreased myelin water fraction and neurite density index compared with lesions in the juxtacortical region (P < 0.0001 and P < 0.05). Similarly, lesions with paramagnetic rims showed decreased myelin water fraction and neurite density index relative to lesions without a rim (P < 0.0001). Also, in 75% of white matter lesions, the reduction in neurite density index was higher than the reduction in the myelin water fraction. Besides, normal-appearing white and grey matter revealed diffuse reduction of myelin water fraction and neurite density index in multiple sclerosis compared to healthy controls (P < 0.01). Further, a more extensive reduction in myelin water fraction and neurite density index in normal-appearing cortex was observed in progressive versus relapsing-remitting participants. Neurite density index in white matter lesions correlated with disability in patients with clinical deficits (P < 0.01, beta = -10.00); and neurite density index and myelin water fraction in white matter lesions were associated to serum neurofilament light chain in the entire patient cohort (P < 0.01, beta = -3.60 and P < 0.01, beta = 0.13, respectively). These findings suggest that (i) myelin and axon pathology in multiple sclerosis is extensive in both lesions and normal-appearing tissue; (ii) particular types of lesions exhibit more damage to myelin and axons than others; (iii) progressive patients differ from relapsing-remitting patients because of more extensive axon/myelin damage in the cortex; and (iv) myelin and axon pathology in lesions is related to disability in patients with clinical deficits and global measures of neuroaxonal damage.
Identifiants
pubmed: 33693571
pii: 6164965
doi: 10.1093/brain/awab088
pmc: PMC8374972
doi:
Substances chimiques
Water
059QF0KO0R
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1684-1696Informations de copyright
© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.
Références
Ann Neurol. 2017 Jun;81(6):811-824
pubmed: 28470695
J Neurol Neurosurg Psychiatry. 2006 Jan;77(1):40-5
pubmed: 16361590
Arch Neurol. 2002 Sep;59(9):1406-12
pubmed: 12223026
AJNR Am J Neuroradiol. 2006 Oct;27(9):2005-11
pubmed: 17032884
Ann Neurol. 2014 May;75(5):728-38
pubmed: 24771535
Neurology. 2009 Jun 2;72(22):1914-21
pubmed: 19487649
J Neurol. 2015 Jan;262(1):1-6
pubmed: 24723117
Arch Neurol. 2007 Mar;64(3):411-5
pubmed: 17353385
PLoS One. 2015 Aug 31;10(8):e0136786
pubmed: 26322632
J Neuroimmunol. 2014 Dec 15;277(1-2):13-7
pubmed: 25262157
NMR Biomed. 2010 Aug;23(7):865-72
pubmed: 20882528
Neuroimage. 2020 Aug 15;217:116906
pubmed: 32387626
Ann Clin Transl Neurol. 2017 Aug 15;4(9):663-679
pubmed: 28904988
J Comput Assist Tomogr. 2002 Jan-Feb;26(1):62-8
pubmed: 11801905
Brain. 2007 Nov;130(Pt 11):2800-15
pubmed: 17956913
J Neuropathol Exp Neurol. 2010 Oct;69(10):1017-1033
pubmed: 20838243
J Neurol. 2007 Apr;254(4):513-8
pubmed: 17401516
Acta Neuropathol. 2017 Jan;133(1):13-24
pubmed: 27988845
Ann Neurol. 1998 Jun;43(6):809-14
pubmed: 9629851
Neuroimage. 2010 Jan 15;49(2):1271-81
pubmed: 19819338
Brain. 1994 Dec;117 ( Pt 6):1311-22
pubmed: 7820568
Magn Reson Med. 2012 Nov;68(5):1536-43
pubmed: 22266707
J Neurol. 2015 Aug;262(8):1909-17
pubmed: 26041614
Neural Regen Res. 2019 Jan;14(1):114-123
pubmed: 30531085
Brain. 2007 Apr;130(Pt 4):1089-104
pubmed: 17438020
Curr Opin Neurol. 2011 Jun;24(3):224-9
pubmed: 21455066
Acta Neuropathol Commun. 2014 May 09;2:53
pubmed: 24887075
Neuroimage. 2016 Nov 15;142:394-406
pubmed: 27523449
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Nat Rev Neurol. 2015 Dec;11(12):676-86
pubmed: 26526531
Brain. 2006 Dec;129(Pt 12):3165-72
pubmed: 16921173
J Neuroimmunol. 2007 Dec;192(1-2):226-34
pubmed: 17997491
Acta Neuropathol. 2017 Jan;133(1):25-42
pubmed: 27796537
Ann Neurol. 2004 Apr;55(4):458-68
pubmed: 15048884
Neuroimage. 2016 Oct 1;139:346-359
pubmed: 27282476
Acta Neuropathol. 2012 May;123(5):627-38
pubmed: 22327362
Neuroimage. 2016 Jan 15;125:739-744
pubmed: 26505297
Neuropathol Appl Neurobiol. 2007 Jun;33(3):277-87
pubmed: 17442065
Neurology. 2014 Jul 15;83(3):278-86
pubmed: 24871874
PLoS One. 2013 Aug 20;8(8):e72822
pubmed: 23977356
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Brain. 1999 Dec;122 ( Pt 12):2279-95
pubmed: 10581222
Brain. 2009 May;132(Pt 5):1175-89
pubmed: 19339255
IEEE Trans Med Imaging. 2012 Mar;31(3):816-24
pubmed: 22231170
NMR Biomed. 2019 Apr;32(4):e3888
pubmed: 29350435
Neuroimage. 2012 Aug 15;62(2):782-90
pubmed: 21979382
Radiology. 2012 Dec;265(3):926-32
pubmed: 23074257
Glia. 2017 Aug;65(8):1350-1360
pubmed: 28560740
Nat Rev Neurosci. 2012 Jun 20;13(7):507-14
pubmed: 22714021
Mult Scler. 2006 Dec;12(6):747-53
pubmed: 17263002
Glia. 2014 Oct;62(10):1645-58
pubmed: 24910450
Front Immunol. 2019 Jan 10;9:3116
pubmed: 30687321
Ann Neurol. 2000 Jun;47(6):707-17
pubmed: 10852536
Brain Pathol. 2018 Sep;28(5):750-764
pubmed: 30375119
Brain. 2005 Nov;128(Pt 11):2705-12
pubmed: 16230320
Ann Neurol. 2004 Sep;56(3):407-15
pubmed: 15349868
Annu Rev Neurosci. 2008;31:247-69
pubmed: 18558855
Neuroimage. 2012 Jul 16;61(4):1000-16
pubmed: 22484410
Neurology. 2001 Oct 9;57(7):1248-52
pubmed: 11591844
Mult Scler. 2014 Sep;20(10):1322-30
pubmed: 24552746
J Neurol. 2005 Nov;252 Suppl 5:v10-5
pubmed: 16254696
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Ann Clin Transl Neurol. 2014 Jun;1(6):423-32
pubmed: 25356412
Acta Neuropathol. 2013 Jun;125(6):841-59
pubmed: 23595275
Neuroimage. 2016 Jan 15;125:1063-1078
pubmed: 26481672
Neuroimage Clin. 2020;27:102335
pubmed: 32663798
N Engl J Med. 2012 Jul 12;367(2):115-23
pubmed: 22784115
Magn Reson Imaging. 2014 Apr;32(3):250-8
pubmed: 24462106
Ann Neurol. 2016 May;79(5):726-738
pubmed: 26891452
Neurology. 2000 Nov 28;55(10):1506-10
pubmed: 11094105
Ann Neurol. 2010 Oct;68(4):465-76
pubmed: 20687208
AJNR Am J Neuroradiol. 2018 Jul;39(7):1233-1238
pubmed: 29724768
Brain. 2000 Jun;123 ( Pt 6):1174-83
pubmed: 10825356
Neuroimage. 2012 Aug 15;62(2):774-81
pubmed: 22248573
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
JAMA Neurol. 2019 Dec 1;76(12):1474-1483
pubmed: 31403674
J Neurosci Res. 2001 Aug 15;65(4):308-17
pubmed: 11494366
Magn Reson Med. 2016 Aug;76(2):456-65
pubmed: 26331978
Neurology. 2011 Feb 1;76(5):418-24
pubmed: 21209373
Ann Neurol. 1998 Jan;43(1):56-71
pubmed: 9450769